ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 879

IL-31 Protein Expression in Lesional Skin Correlates with Itch in Dermatomyositis

Nithin Reddy1,2, Majid Zeidi3 and Victoria P. Werth4, 1Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 2Corporal Michael J. Crescenz VAMC, Philadelphia, PA, 3Philadelphia Veterans Affairs Medical Center, Philadelphia, PA, 4Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Dermatomyositis and interleukins (IL), T cells

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, October 21, 2018

Title: 3S084 ACR Abstract: Muscle Biology, Myositis & Myopathies I: Biomarkers (875–879)

Session Type: ACR Concurrent Abstract Session

Session Time: 2:30PM-4:00PM

Background/Purpose: Dermatomyositis (DM) is an inflammatory myopathy where itch is a major contributor to impaired quality of life. Previously, we have shown that a cytokine responsible for itch in other diseases, interleukin (IL)-31, is elevated in lesional skin of DM patients. We aim to i) demonstrate the correlation between IL-31 protein expression in lesional skin and clinical assessment tools of itch severity and disease activity; ii) investigate the relationship between IL-31 protein expression in DM responders vs. non-responders in terms of itch and disease activity; iii) identify the cellular source of IL-31 in DM.

Methods: IL-31 protein expression in skin was quantified using immunohistochemistry (IHC) analysis of lesional skin samples of 12 DM patients at two separate time points. The visual analog scale (VAS), and SKINDEX-29 Symptoms Score clinical assessment tools, and Cutaneous Disease and Activity Severity Index (CDASI) were used to evaluate itch and disease activity. IHC co-localization of CD4, IL-31, and either IFN-gamma (Th1) or IL-4 (Th2) was performed on baseline lesional skin samples from 5 DM patients to identify the cellular source of IL-31.

Results: IL-31 expression with respect to mean cell intensity in lesional skin was highly correlated with SKINDEX-29 Symptoms Score, SKINDEX-29 question 10, and VAS itch score (r=0.85, p<0.001; r=0.77, p<0.01; r=0.68, p<0.05 respectively). IL-31 expression with respect to area stained was highly correlated with CDASI (r=0.78, p<0.01). These correlations were maintained at visit 6 (r=0.65, p<0.05; r=0.64, p<0.05; r=0.60, p<0.05; r=0.74, p<0.01). Itch responders had a greater reduction of IL-31 relative to non-responders with respect to mean cell intensity (p<0.05). Disease responders had a greater reduction in IL-31 staining area relative to non-responders (p<0.05). IHC co-staining of IL-31 with Th1 and Th2 markers demonstrated strong co-localization of IL-31 with Th1 T-cells and relatively little Th2 production of IL-31.

Conclusion: IL-31 cell intensity in lesional skin correlates strongly with itch severity while IL-31 staining area is highly correlated with disease activity. The source of IL-31 in DM is likely to be from Th1 cells rather than Th2 cells.


Disclosure: N. Reddy, None; M. Zeidi, None; V. P. Werth, CLASI, 4.

To cite this abstract in AMA style:

Reddy N, Zeidi M, Werth VP. IL-31 Protein Expression in Lesional Skin Correlates with Itch in Dermatomyositis [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/il-31-protein-expression-in-lesional-skin-correlates-with-itch-in-dermatomyositis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/il-31-protein-expression-in-lesional-skin-correlates-with-itch-in-dermatomyositis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology